Long

Two healthcare leaders, which one is best to own?

& are leading the sectors recovery.

Both are in the Medical Products Industry for diabetes.

Insulent (PODD) normally outperforms DexCom (DXCM) during and after a correction. Then, when they are in sustained uptrends, DXCM outperforms.

For the recent correction, PODD has a -45% deep base while DXCM has a -58%.

PODD bottmed 4 weeks before DXCM, but DXCM has rallied +74% and PODD +65% since.

So, it really depends on your strategy. If you are looking for aplha then is the stock for you but, if you prefer low beta then is better.

Remember that aplha plays in both ways!

Which are you trading?

I'll trade the first that makes a new high.

dpuleo19

Also on:

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.